Friday, July 10, 2026
🇺🇸 FDA

pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis

PARItec

Pari Pharma GmbH

PARItec drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
Status
Public
HQ
Starnberg, DE
Employees
28
Programs
248
Drugs
362
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Drug Pipeline

PARItec pipeline

Portfolio lens on 200 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

PARItec drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

200 compounds

  2. abacavir

    Antiinfectives for systemic use (J05)

    US regulatory status: approved.

  4. aciclovir

    Development asset linked to PARItec in public FDA and regional records. Molecular target: DNA polymerase catalytic subunit.

    Target
    DNA polymerase catalytic subunit
    Mechanism
    Human herpesvirus 1 DNA polymerase inhibitor

  5. acyclovir sodium

    US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.

    Target
    DNA polymerase catalytic subunit
    Mechanism
    Human herpesvirus 1 DNA polymerase inhibitor

  6. adalimumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  7. adrenaline (epinephrine)

    Development asset linked to PARItec in public FDA and regional records. Molecular target: Adrenergic receptor.

    Target
    Adrenergic receptor
    Mechanism
    Adrenergic receptor agonist

  8. air

    US regulatory status: approved.

  9. alcohol

    US regulatory status: approved.

  10. aldesleukin

    US regulatory status: approved. Molecular target: Interleukin-2 receptor.

    Target
    Interleukin-2 receptor
    Mechanism
    Interleukin-2 receptor agonist

  12. allopurinol

    Musculo-skeletal system (M04)

    US regulatory status: approved. Molecular target: Xanthine dehydrogenase/oxidase.

    Target
    Xanthine dehydrogenase/oxidase
    Mechanism
    Xanthine dehydrogenase inhibitor

  14. alzheimer

    Development asset linked to PARItec in public FDA and regional records.

  15. ambrisentan

    Cardiovascular system (C02)

    US regulatory status: approved. Molecular target: Endothelin receptor, ET-A/ET-B.

    Target
    Endothelin receptor, ET-A/ET-B
    Mechanism
    Endothelin receptor, ET-A/ET-B antagonist

  16. amikacin

    Antiinfectives for systemic use (J01)

    Antiinfectives for systemic use (J01) compound in PARItec's portfolio.

  17. amiodarone

    Development asset linked to PARItec in public FDA and regional records. Mechanism: HERG blocker.

    Mechanism
    HERG blocker

  18. amoxicillin

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  19. amphotericin b

    US regulatory status: approved. Molecular target: Ergosterol.

    Target
    Ergosterol
    Mechanism
    Ergosterol sequestering agent

  20. ampicillin sodium

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  21. anakinra

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-1 receptor type 1.

    Target
    Interleukin-1 receptor type 1
    Mechanism
    Interleukin-1 receptor antagonist

  22. anidulafungin

    Antiinfectives for systemic use (J02)

    US regulatory status: approved. Molecular target: 1,3-beta-glucan synthase.

    Target
    1,3-beta-glucan synthase
    Mechanism
    1,3-beta-glucan synthase inhibitor

  23. anti-

    Development asset linked to PARItec in public FDA and regional records.

  24. anti-melanoma mab fragments

    Various (V09)

    Various (V09) compound in PARItec's portfolio. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  25. antibody

    Development asset linked to PARItec in public FDA and regional records.

  26. apixaban

    Blood and blood forming organs (B01)

    US regulatory status: approved. Molecular target: Coagulation factor X.

    Target
    Coagulation factor X
    Mechanism
    Coagulation factor X inhibitor

  27. ascorbic acid

    US regulatory status: approved. Mechanism: Supplement.

    Mechanism
    Supplement

  28. aspirin

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  29. atezolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  30. atomoxetine hydrochloride

    US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.

    Target
    Sodium-dependent noradrenaline transporter
    Mechanism
    Norepinephrine transporter inhibitor

  31. atropine sulfate

    Sensory organs (S01)

    US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.

    Target
    Muscarinic acetylcholine receptor M1
    Mechanism
    Muscarinic acetylcholine receptor M3 antagonist

  32. autologous

    Development asset linked to PARItec in public FDA and regional records.

  33. azathioprine

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.

    Target
    Amidophosphoribosyltransferase
    Mechanism
    Amidophosphoribosyltransferase inhibitor

  34. azathioprine sodium

    US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.

    Target
    Amidophosphoribosyltransferase
    Mechanism
    Amidophosphoribosyltransferase inhibitor

  35. azithromycin

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Bacterial 70S ribosome inhibitor

  36. baricitinib

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase JAK1.

    Target
    Tyrosine-protein kinase JAK1
    Mechanism
    Tyrosine-protein kinase JAK2 inhibitor

  37. beclomethasone dipropionate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  38. bedaquiline

    Antiinfectives for systemic use (J04)

    Antiinfectives for systemic use (J04) compound in PARItec's portfolio.

  39. belimumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor ligand superfamily member 13B.

    Target
    Tumor necrosis factor ligand superfamily member 13B
    Mechanism
    Tumor necrosis factor ligand superfamily member 13B inhibitor

  41. betamethasone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  42. bevacizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  43. biological

    Development asset linked to PARItec in public FDA and regional records.

  44. bisoprolol

    Development asset linked to PARItec in public FDA and regional records. Mechanism: Beta-1 adrenergic receptor antagonist.

    Mechanism
    Beta-1 adrenergic receptor antagonist

  45. blinatumomab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD19.

    Target
    B-lymphocyte antigen CD19
    Mechanism
    T cell surface glycoprotein CD3 cross-linking agent

  46. bortezomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  47. bosentan

    Cardiovascular system (C02)

    US regulatory status: approved. Molecular target: Endothelin receptor, ET-A/ET-B.

    Target
    Endothelin receptor, ET-A/ET-B
    Mechanism
    Endothelin receptor, ET-A/ET-B antagonist

  48. botulinum toxin type a

    Musculo-skeletal system (M03)

    Musculo-skeletal system (M03) compound in PARItec's portfolio. Molecular target: Synaptosomal-associated protein 25.

    Target
    Synaptosomal-associated protein 25
    Mechanism
    Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme

  49. brentuximab vedotin

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  50. calcium

    US regulatory status: approved.

  52. calcium chloride

    US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.

    Mechanism
    Dihydrofolate reductase inhibitor

  53. cannabidiol

    Nervous system (N03)

    US regulatory status: approved. Molecular target: Cannabinoid receptor 1.

    Target
    Cannabinoid receptor 1
    Mechanism
    Cannabinoid CB1 receptor negative allosteric modulator

  54. capsule

    Development asset linked to PARItec in public FDA and regional records.

  55. capsules

    Development asset linked to PARItec in public FDA and regional records.

  56. carboplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  57. carfilzomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  58. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  59. carvedilol

    US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.

    Target
    Adrenergic receptor alpha-1
    Mechanism
    Adrenergic receptor beta antagonist

  60. caspofungin

    Antiinfectives for systemic use (J02)

    Antiinfectives for systemic use (J02) compound in PARItec's portfolio.

  61. cefazolin

    Development asset linked to PARItec in public FDA and regional records.

  62. cefazolin sodium

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  63. cefepime

    Antiinfectives for systemic use (J01)

    Antiinfectives for systemic use (J01) compound in PARItec's portfolio.

  64. cefixime

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  65. cefotaxime sodium

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  66. ceftaroline fosamil

    Antiinfectives for systemic use (J01)

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  67. ceftazidime

    Antiinfectives for systemic use (J01)

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  68. ceftolozane

    Antiinfectives for systemic use (J01)

    Antiinfectives for systemic use (J01) compound in PARItec's portfolio.

  69. ceftriaxone

    Development asset linked to PARItec in public FDA and regional records.

  70. ceftriaxone sodium

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  71. cells

    Development asset linked to PARItec in public FDA and regional records.

  72. cend-

    Development asset linked to PARItec in public FDA and regional records.

  73. certolizumab pegol

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  74. chemotherapy

    Development asset linked to PARItec in public FDA and regional records.

  75. chlorhexidine

    Development asset linked to PARItec in public FDA and regional records.

  76. chloride

    Development asset linked to PARItec in public FDA and regional records.

  77. ciclosporin

    Sensory organs (S01)

    Sensory organs (S01) compound in PARItec's portfolio. Molecular target: Peptidyl-prolyl cis-trans isomerase A.

    Target
    Peptidyl-prolyl cis-trans isomerase A
    Mechanism
    Cyclophilin A modulator

  78. cilostazol

    US regulatory status: approved. Molecular target: cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A.

    Target
    cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
    Mechanism
    Phosphodiesterase 3A inhibitor

  79. ciprofloxacin

    US regulatory status: approved. Molecular target: Bacterial DNA gyrase.

    Target
    Bacterial DNA gyrase
    Mechanism
    Bacterial DNA gyrase inhibitor

  80. ciprofloxacin hydrochloride

    US regulatory status: approved. Molecular target: Bacterial DNA gyrase.

    Target
    Bacterial DNA gyrase
    Mechanism
    Bacterial DNA gyrase inhibitor

  81. cisplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  82. clarithromycin

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Bacterial 70S ribosome inhibitor

  83. clindamycin

    Development asset linked to PARItec in public FDA and regional records.

  84. clobazam

    US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    GABA-A receptor; anion channel positive allosteric modulator

  85. clobetasol

    Development asset linked to PARItec in public FDA and regional records.

  86. clobetasol propionate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  87. clofazimine

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  88. colchicine

    Musculo-skeletal system (M04)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  89. combination

    Development asset linked to PARItec in public FDA and regional records.

  90. control

    Development asset linked to PARItec in public FDA and regional records.

  91. conventional

    Development asset linked to PARItec in public FDA and regional records.

  92. cortisone

    Development asset linked to PARItec in public FDA and regional records.

  93. cyclophosphamide

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  94. cytarabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  95. dalbavancin

    Antiinfectives for systemic use (J01)

    Antiinfectives for systemic use (J01) compound in PARItec's portfolio.

  96. dapagliflozin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.

    Target
    Sodium/glucose cotransporter 2
    Mechanism
    Sodium/glucose cotransporter 2 inhibitor

  97. daptomycin

    Antiinfectives for systemic use (J01)

    US regulatory status: approved. Molecular target: Cell membrane.

    Target
    Cell membrane
    Mechanism
    Cell membrane inhibitor

  98. daratumumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

    Target
    ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
    Mechanism
    Lymphocyte differentiation antigen CD38 inhibitor

  99. delafloxacin

    Antiinfectives for systemic use (J01)

    Antiinfectives for systemic use (J01) compound in PARItec's portfolio.

  100. desmopressin acetate

    US regulatory status: approved. Molecular target: Vasopressin receptor.

    Target
    Vasopressin receptor
    Mechanism
    Vasopressin receptor agonist

  101. dexamethasone

    Systemic hormonal preparations (H02)

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  102. dexamethasone phosphate

    Systemic hormonal preparations (H02)

    Systemic hormonal preparations (H02) compound in PARItec's portfolio.

  103. dexamethasone sodium phosphate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  104. dexmedetomidine

    Nervous system (N05)

    Nervous system (N05) compound in PARItec's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.

    Mechanism
    Adrenergic receptor alpha-2 agonist

  106. diethylpropion hydrochloride

    US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.

    Target
    Sodium-dependent dopamine transporter
    Mechanism
    Norepinephrine transporter inhibitor

  107. diltiazem

    Development asset linked to PARItec in public FDA and regional records. Mechanism: Voltage-gated L-type calcium channel blocker.

    Mechanism
    Voltage-gated L-type calcium channel blocker

  108. dimethyl

    Development asset linked to PARItec in public FDA and regional records.

  109. dimethyl fumarate

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Kelch-like ECH-associated protein 1.

    Target
    Kelch-like ECH-associated protein 1
    Mechanism
    Kelch-like ECH-associated protein 1 inhibitor

  110. donepezil

    Development asset linked to PARItec in public FDA and regional records. Mechanism: Acetylcholinesterase inhibitor.

    Mechanism
    Acetylcholinesterase inhibitor

  111. donepezil hydrochloride

    US regulatory status: approved. Molecular target: Acetylcholinesterase.

    Target
    Acetylcholinesterase
    Mechanism
    Acetylcholinesterase inhibitor

  112. dose

    Development asset linked to PARItec in public FDA and regional records.

  113. doxycycline

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Matrix metalloproteinase 8 inhibitor

  114. doxycycline hyclate

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Matrix metalloproteinase-1 inhibitor

  116. dulaglutide

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.

    Target
    Glucagon-like peptide 1 receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist

  117. durvalumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  118. eculizumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Complement C5.

    Target
    Complement C5
    Mechanism
    Complement C5 inhibitor

  119. embolic

    Development asset linked to PARItec in public FDA and regional records.

  120. endocrine

    Development asset linked to PARItec in public FDA and regional records.

  121. enoxaparin

    Development asset linked to PARItec in public FDA and regional records.

  122. enoxaparin sodium

    Blood and blood forming organs (B01)

    US regulatory status: approved. Molecular target: Antithrombin-III.

    Target
    Antithrombin-III
    Mechanism
    Antithrombin-III activator

  123. epinephrine

    Cardiovascular system (C01)

    US regulatory status: approved. Molecular target: Adrenergic receptor.

    Target
    Adrenergic receptor
    Mechanism
    Adrenergic receptor agonist

  124. erythromycin lactobionate

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Bacterial 70S ribosome inhibitor

  125. estropipate

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  126. ethinyl estradiol

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  127. ethiodized oil

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  128. etoposide

    US regulatory status: approved. Molecular target: DNA topoisomerase II.

    Target
    DNA topoisomerase II
    Mechanism
    DNA topoisomerase II inhibitor

  129. evolocumab

    Cardiovascular system (C10)

    US regulatory status: approved. Molecular target: Proprotein convertase subtilisin/kexin type 9.

    Target
    Proprotein convertase subtilisin/kexin type 9
    Mechanism
    Subtilisin/kexin type 9 inhibitor

  130. experimental

    Development asset linked to PARItec in public FDA and regional records.

  131. extracellular

    Development asset linked to PARItec in public FDA and regional records.

  132. fampridine

    Nervous system (N07)

    Nervous system (N07) compound in PARItec's portfolio. Molecular target: Voltage-gated potassium channel.

    Target
    Voltage-gated potassium channel
    Mechanism
    Voltage-gated potassium channel blocker

  133. febuxostat

    Musculo-skeletal system (M04)

    US regulatory status: approved. Molecular target: Xanthine dehydrogenase/oxidase.

    Target
    Xanthine dehydrogenase/oxidase
    Mechanism
    Xanthine dehydrogenase inhibitor

  134. fentanyl citrate

    US regulatory status: approved. Molecular target: Mu-type opioid receptor.

    Target
    Mu-type opioid receptor
    Mechanism
    Mu opioid receptor agonist

  137. filgrastim

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.

    Target
    Granulocyte colony-stimulating factor receptor
    Mechanism
    Granulocyte colony stimulating factor receptor agonist

  138. flecainide

    Development asset linked to PARItec in public FDA and regional records. Mechanism: Sodium channel protein type V alpha subunit blocker.

    Mechanism
    Sodium channel protein type V alpha subunit blocker

  139. flecainide acetate

    US regulatory status: approved. Molecular target: Sodium channel protein type 5 subunit alpha.

    Target
    Sodium channel protein type 5 subunit alpha
    Mechanism
    Sodium channel protein type V alpha subunit blocker

  140. fluconazole

    US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.

    Target
    Lanosterol 14-alpha demethylase
    Mechanism
    Cytochrome P450 51 inhibitor

  141. fludarabine

    Development asset linked to PARItec in public FDA and regional records.

  142. fludarabine phosphate

    US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).

    Target
    DNA polymerase (alpha/delta/epsilon)
    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  143. fludeoxyglucose f-18

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  144. fludrocortisone

    Development asset linked to PARItec in public FDA and regional records.

  145. fluorouracil

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  146. folic

    Development asset linked to PARItec in public FDA and regional records.

  147. folic acid

    Various (V04)

    US regulatory status: approved.

  148. ganciclovir

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.

    Target
    DNA polymerase catalytic subunit
    Mechanism
    Human herpesvirus 1 DNA polymerase inhibitor

  149. gemcitabine

    US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.

    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  150. gentamicin sulfate

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Bacterial 70S ribosome inhibitor

  151. glibenclamide

    Alimentary tract and metabolism (A10)

    Alimentary tract and metabolism (A10) compound in PARItec's portfolio. Molecular target: Sulfonylurea receptor 1, Kir6.2.

    Target
    Sulfonylurea receptor 1, Kir6.2
    Mechanism
    Sulfonylurea receptor 1, Kir6.2 blocker

  152. glucarpidase

    Various (V03)

    US regulatory status: approved. Molecular target: Methotrexate.

    Target
    Methotrexate
    Mechanism
    Methotrexate hydrolytic enzyme

  153. glucocorticoid

    Development asset linked to PARItec in public FDA and regional records.

  154. glycerol phenylbutyrate

    Alimentary tract and metabolism (A16)

    US regulatory status: approved. Molecular target: Glutamine.

    Target
    Glutamine
    Mechanism
    Glutamine sequestering agent

  155. group

    Development asset linked to PARItec in public FDA and regional records.

  156. hema-

    Development asset linked to PARItec in public FDA and regional records.

  157. heparin

    Development asset linked to PARItec in public FDA and regional records. Molecular target: Antithrombin-III.

    Target
    Antithrombin-III
    Mechanism
    Antithrombin-III activator

  158. hexachlorophene

    US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.

    Target
    Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
    Mechanism
    Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor

  159. high-dose

    Development asset linked to PARItec in public FDA and regional records.

  161. human normal immunoglobulin (ivig)

    Antiinfectives for systemic use (J06)

    Antiinfectives for systemic use (J06) compound in PARItec's portfolio. Mechanism: Replacement therapy, immunomodulatory effects.

    Mechanism
    Replacement therapy, immunomodulatory effects

  164. hydrocortisone

    Systemic hormonal preparations (H02)

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  165. hydrogen

    Development asset linked to PARItec in public FDA and regional records.

  166. hydroxychloroquine

    Development asset linked to PARItec in public FDA and regional records. Mechanism: Toll-like receptor 7 antagonist.

    Mechanism
    Toll-like receptor 7 antagonist

  167. hydroxychloroquine sulfate

    US regulatory status: approved. Molecular target: Ferriprotoporphyrin IX.

    Target
    Ferriprotoporphyrin IX
    Mechanism
    Toll-like receptor 9 antagonist

  168. idarubicin

    Development asset linked to PARItec in public FDA and regional records. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  169. idarubicin hydrochloride

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA topoisomerase II alpha inhibitor

  170. imatinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in PARItec's portfolio. Mechanism: Tyrosine-protein kinase ABL inhibitor.

    Mechanism
    Tyrosine-protein kinase ABL inhibitor

  171. imipenem

    Antiinfectives for systemic use (J01)

    Antiinfectives for systemic use (J01) compound in PARItec's portfolio. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  172. incobotulinumtoxina

    US regulatory status: approved. Molecular target: Synaptosomal-associated protein 25.

    Target
    Synaptosomal-associated protein 25
    Mechanism
    Synaptosomal-associated protein 25 inhibitor

  173. individual

    Development asset linked to PARItec in public FDA and regional records.

  174. induction

    Development asset linked to PARItec in public FDA and regional records.

  175. infliximab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  177. infusion

    Development asset linked to PARItec in public FDA and regional records.

  178. inhalation

    Development asset linked to PARItec in public FDA and regional records.

  179. inhibitor

    Development asset linked to PARItec in public FDA and regional records.

  180. injectable

    Development asset linked to PARItec in public FDA and regional records.

  181. injection

    Development asset linked to PARItec in public FDA and regional records.

  182. intensive

    Development asset linked to PARItec in public FDA and regional records.

  183. interferon alfa-2b

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.

    Target
    Interferon alpha/beta receptor
    Mechanism
    Interferon alpha/beta receptor agonist

  184. interferon gamma-1b

    US regulatory status: approved. Molecular target: Interferon gamma receptor.

    Target
    Interferon gamma receptor
    Mechanism
    Interferon gamma receptor agonist

  185. intravenous

    Development asset linked to PARItec in public FDA and regional records.

  186. intravitreal

    Development asset linked to PARItec in public FDA and regional records.

  187. iodixanol

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  188. ioversol

    US regulatory status: approved.

  189. irbesartan

    Cardiovascular system (C09)

    US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.

    Target
    Type-1 angiotensin II receptor
    Mechanism
    Type-1 angiotensin II receptor antagonist

  190. irinotecan

    Development asset linked to PARItec in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.

    Mechanism
    DNA topoisomerase I inhibitor

  191. iron sucrose

    US regulatory status: approved. Mechanism: Supplement.

    Mechanism
    Supplement

  192. isatuximab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in PARItec's portfolio. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

    Target
    ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
    Mechanism
    Lymphocyte differentiation antigen CD38 inhibitor

  193. isavuconazole

    Antiinfectives for systemic use (J02)

    Antiinfectives for systemic use (J02) compound in PARItec's portfolio.

  194. isavuconazonium sulfate

    US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.

    Target
    Lanosterol 14-alpha demethylase
    Mechanism
    Lanosterol 14-alpha demethylase inhibitor

  195. isoniazid

    US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH].

    Target
    Enoyl-[acyl-carrier-protein] reductase [NADH]
    Mechanism
    Enoyl-[acyl-carrier-protein] reductase inhibitor

  196. ivabradine

    Cardiovascular system (C01)

    US regulatory status: approved. Molecular target: Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4.

    Target
    Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4
    Mechanism
    Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker

  197. ketorolac tromethamine

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  198. lacosamide

    Nervous system (N03)

    US regulatory status: approved. Molecular target: Sodium channel alpha subunit.

    Target
    Sodium channel alpha subunit
    Mechanism
    Sodium channel alpha subunit blocker

  199. leflunomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Dihydroorotate dehydrogenase (quinone), mitochondrial.

    Target
    Dihydroorotate dehydrogenase (quinone), mitochondrial
    Mechanism
    Dihydroorotate dehydrogenase inhibitor

  200. lenalidomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.

    Target
    CRL4(CRBN) E3 ubiquitin ligase
    Mechanism
    CRL4(CRBN) E3 ubiquitin ligase inhibitor

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.